Latest on Anabolic Agents for Osteoporosis Treatment

被引：2

作者：

di Filippo, Luigi ^{[1
,2
]}

Rosen, Clifford J. ^{[3
]}

机构：

[1] Univ Vita Salute San Raffaele, Inst Endocrine & Metab Sci, Milan, Italy

[2] IRCCS Osped San Raffaele, Milan, Italy

[3] Main Ehlth Inst Res, Ctr Clin & Translat Res, Scarborough, ME 04074 USA

来源：

ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA | 2024年 / 53卷 / 04期

关键词：

Osteoporosis; Anabolics; Teriparatide; Abaloparatide; Romosozumab; Blosozumab; Fragility fractures; Glucocorticoids; PARATHYROID-HORMONE; 1-34; BONE-MINERAL DENSITY; POSTMENOPAUSAL WOMEN; DOUBLE-BLIND; ABALOPARATIDE; TERIPARATIDE; ROMOSOZUMAB; FRACTURE; RISK; PLACEBO;

D O I：

10.1016/j.ecl.2024.08.003

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

The efficacies of anabolic compounds in preventing fragility fractures and increasing BMD were progressively and widely demonstrated in the last decades. Latest updated clinical data (Table 1) in this setting have markedly downgrading their potential serious side effects including risk of malignancies in teriparatide- and cardiovascular events in romosozumab-users, respectively. Further future data are warranted about their potential efficacy in patients with GIO and, interestingly, their use is currently investigated also in fracture healings setting.

引用

页码：513 / 523

页数：11

共 50 条

[41] ANABOLIC THERAPY AND OPTIMAL TREATMENT SEQUENCES FOR PATIENTS WITH OSTEOPOROSIS AT HIGH RISK FOR FRACTURE
Cosman, Felicia
ENDOCRINE PRACTICE, 2020, 26 (07) : 777 - 786
[42] Role of bone-forming agents in the management of osteoporosis
Michael R. McClung
Aging Clinical and Experimental Research, 2021, 33 : 775 - 791
[43] Combination Anabolic and Antiresorptive Therapy for Osteoporosis
Cusano, Natalie E.
Bilezikian, John P.
ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA, 2012, 41 (03) : 643 - +
[44] Role of bone-forming agents in the management of osteoporosis
McClung, Michael R.
AGING CLINICAL AND EXPERIMENTAL RESEARCH, 2021, 33 (04) : 775 - 791
[45] Combination therapy of anabolic and nonbisphosphonates antiresorptive agents for the treatment of osteoporosis: A meta-analysis
Lou, Shenghan
Wang, Lifan
Wang, Yiwen
Jiang, Yunduo
Liu, Jingwei
Wang, Yansong
MEDICINE, 2017, 96 (52)
[46] Anabolic Therapies in Osteoporosis and Bone Regeneration
Russow, Gabriele
Jahn, Denise
Appelt, Jessika
Maerdian, Sven
Tsitsilonis, Serafeim
Keller, Johannes
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2019, 20 (01)
[47] Anabolic Therapy for the Treatment of Osteoporosis in Childhood
Ward, Leanne M.
Rauch, Frank
CURRENT OSTEOPOROSIS REPORTS, 2018, 16 (03): : 269 - 276
[48] The use of PTH in the treatment of osteoporosis
Cochenski Borba, Victoria Z.
Pietszkowski Manas, Nadila Cecyn
ARQUIVOS BRASILEIROS DE ENDOCRINOLOGIA E METABOLOGIA, 2010, 54 (02) : 213 - 219
[49] Effects of Teriparatide Treatment on Bone Mineral Density in Patients With Osteoporosis: A Short-Term Dose-Response Study
Roy, Amarendra Nath
Mazumdar, Ipsita
CUREUS JOURNAL OF MEDICAL SCIENCE, 2023, 15 (09)
[50] Biological agents in management of osteoporosis
Tella, Sri Harsha
Gallagher, J. Christopher
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2014, 70 (11) : 1291 - 1301

← 1 2 3 4 5 →